Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells

Cytokine

Volumn 12, Issue 4, 2000, Pages 339-347

  Gnant, Michael F X ^a   Turner, Ewa M ^a   Alexander Jr , H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytokines; Endothelial cells; Hyperthemia; Tissue factor; Tumour necrosis factor

Indexed keywords

CD31 ANTIGEN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; PADGEM PROTEIN; RANTES; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; BLOOD CLOTTING; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPERTHERMIA; INFLAMMATION; PRIORITY JOURNAL; UMBILICAL VEIN;

EID: 0033923246     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0568     Document Type: Article

References (46)

1. Lowy AM, Curley SA. Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors. Surg Oncol Clin N Am. 5:1996;429-441.
2. Lejeune FJ, Lienard D, Douaihy ME. Results of 206 isolated limb perfusions for malignant melanoma. Eur J Cancer Clin Oncol. 15:1989;510-519.
3. Alexander HR, Bartlett DL, Fraker DL, Libutti SK, Moser T, Rosenberg SA. Results of a Phase II study of isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan for unresectable primary or metastatic cancer confined to the liver. Proc Soc Surg Oncol. 6:1997;8.
4. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am. 4:1998;2-11.
5. Fraker DL, Alexander HR, Thom AK. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock. 44:1994;45-50.
6. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 72:1975;3666-3670.
7. Prober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Bock G, Marsh J. Tumour necrosis factor and related cytotoxins. 1984;170-185 Wiley, Chichester.
8. Clauss M, Ryan J, Stern D. Modulation of endothelial cell haemostatis properties by TNF: Insights into the role of endothelium in the most response to inflammatory stimuli. Beutler D. Tumour Necrosis Factors, The molecules and their emerging role in medicine. 1992;49-64 Raven Press, New York.
9. Nawroth P, Handley D, Matsueda G, de Waal R, Gerlach H, Blohm D, Stern D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med. 168:1988;637-647.
10. Olieman AFT, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol. 4:1997;64-69.
11. Eggermont AM, Schraffordt KH, Klausner JM, Lienard D, Kroon BB, Schlag PM, Ben-Air G, Lejeune FJ. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Semin Oncol. 24:1997;547-555.
12. Deshirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol. 24:1997;616-625.
13. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis -Dichlorodiammineplatinum(II) and Mitomycin C. Cancer Res. 40:1980;1165-1168.
14. Hahn GM, Strande DP. Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. J Natl Cancer Inst. 57:1976;1063-1067.
15. Fajardo LF, Schreiber AB, Kelly NI, Hahn GM. Thermal sensitivity of endothelial cells. Radiat Res. 103:1985;276-285.
16. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 44:1984;605-612.
17. Fajardo LF, Prionas SD. Endothelial cells and hyperthermia. Int J Hyperthermia. 10:1994;347-353.
18. Scheid P. Funktionale Besonderheiten der Mikrozirkulation im Karzinom. Biblitheka Anatomica. 1:1961;327-335.
19. Denekamp J. Vascular endothelium as the vulnerable element in tumors. Acta Radiol Oncol. 23:1984;217-225.
20. Alexander HR, Fraker DL. Continuous hyperthermic peritoneal perfusion with cisplatin in the treatment of peritoneal carcinomatosis. Reg Cancer Treat. 8:1995;2-7.
21. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 80:1997;2084-2090.
22. Sumida M, Isawa E, Kobayashi K, Inaba H, Fujimoto S. TNF-α and endotoxin serum levels in cancer patients undergoing intraperitoneal hyperthermic perfusion. Int J Hyperthermia. 12:1996;607-615.
23. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol. 12:1996;416-428.
24. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 16:1998;1479-1489.
25. Thom AK, Alexander HR, An drich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol. 13:1995;264-273.
26. Alexander HR, Bartlett DL, Fraker DL, Libutti SK. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. DeVita VT Jr., Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 1996;1-19 J. B. Lippincott, Philadelphia.
27. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer. 57:1994;656-663.
28. Waight-Sharma A, Grooby W, Betts WH, Russ GR. Effects of in vitro hyperthermia on the expression of adhesion molecules in cytokine-stimulated human umbilical vein endothelial cells. Transplant Proc. 24:1992;2319-2320.
29. Wojta J, Holzer M, Hufnagl P, Christ G, Hoover RL, Binder BR. Hyperthermia stimulates plasminogen activator inhibitor Type 1 expression in human umbilical vein endothelial cellsin vitro. Am J Pathol. 139:1991;911-919.
30. Ang C, Dawes J. The effects of hyperthermia on human endothelial monolayers: modulation of thrombotic potential and permeability. Blood Coagul Fibrinolysis. 5:1994;193-199.
31. Nilsen NO. Endothelial changes and microvascular leakage due to hyperthermia in chick embryos. Virchows Arch. 46:1984;165-174.
32. Fukao H, Hagiya Y, Ueshima S, Okada K, Takaish T, Izaki S, Matsuo O. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells. Thromb Haemost. 75:1996;352-358.
33. Lin P-S, Quamo S, Ho K-C, Gladding J. Hyperthermia enhances the cytotoxic effects of reactive oxygen species to Chinese hamster cells and bovine endothelial cells in vitro. Radiat Res. 126:1991;43-51.
34. Lin JC, Park HJ, Song CW. Combined treatment of IL-1α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia. 12:1996;335-344.
35. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A. 84:1987;9238-9242.
36. Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine. 3:1991;165-183.
37. Rûegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integran αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ Nature Med. 4:1998;408-414.
38. Brand K, Lübbe AS, Justus DJ. Hyperthermia decreases cytokine-mediated adhesion molecule expression on human umbilical vein endothelial cells. Int J Hyperthermia. 12:1996;527-538.
39. Lefor AT, Foster CE, Sartor W, Engbrecht B, Fabian DF, Silverman D. Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte adhesion to endothelial cells. Surgery. 116:1994;214-221.
40. Fajardo LF, Prionas SD, Kowalski J, Kwan HH. Hyperthermia inhibits angiogenesis. Radiat Res. 114:1988;297-306.
41. Cheung N, Wong MP, Yuen ST, Chung LP. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol. 29:1998;910-914.
42. Roizin-Towle L, Pirro JP. Thermotolerance in human cells of normal and neoplastic origin. Int J Hyperthermia. 4:1988;665-675.
43. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, Jain RK. Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res. 55:1995;4824-4829.
44. Ketis NV, Lawler J, Bendena WG. Extracellular matrix components affect the pattern of protein synthesis of endothelial cells responding to hyperthermia. In Vitro Cell Dev Biol. 29:1993;768-772.
45. Srinivasan JM, Fajardo LF, Hahn GM. Mechanism of antitumor activity of tumor necrosis factor α with hyperthermia in a tumor necrosis factor α-resistant tumor. JNCI. 82:1990;1904-1910.
46. Folkman J. Addressing tumor blood vessels. Nat Biotechnol. 15:1997;510.